T-allo10

T-allo10 is an investigational cell therapy product composed of donor-derived allogeneic CD4+ T cells enriched for type 1 regulatory T (Tr1) cells. These are generated ex vivo by coculturing donor CD4+ T cells with tolerogenic dendritic cells (DC-10s) for 10 days, resulting in a population that is specific for host alloantigens and capable of suppressing host-reactive immune responses. The primary mechanism involves suppression of graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HSCT), while supporting immune reconstitution. Tr1 cells mediate their effects through high expression of CTLA-4 and PD-1, as well as secretion of IL-10, leading to targeted immunosuppression without global immune compromise. The therapy aims to reduce the incidence and severity of GvHD in patients receiving mismatched related or unrelated donor HSCT for hematologic malignancies such as acute lymphoblastic leukemia. Clinical trials have demonstrated safety and promising efficacy in pediatric and young adult populations[2][3][5][7][9].

Other names

alloantigen-specific allogeneic type 1 regulatory T cellsTr1-enriched cell productTr-1-enriched cell productTr 1-enriched cell product